An update from Foghorn Therapeutics (FHTX) is now available.
Foghorn Therapeutics Inc. is set to share updates on its cancer research pipeline during a conference call and webcast on April 9, 2024, coinciding with the AACR Annual Meeting. The company will outline progress in its preclinical trials, including the development of promising new inhibitors and degraders, with the intention of engaging with investors about these advancements. These forward-looking statements, while offering insights into potential future successes, come with the usual caveats of uncertainty inherent in clinical trials and the pharmaceutical industry.
Learn more about FHTX stock on TipRanks’ Stock Analysis page.
